Anti-nucleosome antibodies: A potential surrogate marker for renal affection in lupus patients with insignificant proteinuria  by El Bakry, Samah A. et al.
The Egyptian Rheumatologist (2014) 36, 79–84Egyptian Society for Joint Diseases and Arthritis
The Egyptian Rheumatologist
www.rheumatology.eg.net
www.sciencedirect.comORIGINAL ARTICLEAnti-nucleosome antibodies: A potential surrogate
marker for renal aﬀection in lupus patients with
insigniﬁcant proteinuria* Corresponding author. Address: Building 6- Makka st. El Sefarat
district, Nasr City, Cairo, Egypt. Tel.: +20 0122 7432489.
E-mail address: samahmn72@yahoo.com (S.A. El Bakry).
Peer review under responsibility of Egyptian Society for Joint Diseases
and Arthritis.
Production and hosting by Elsevier
1110-1164  2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and Arthritis.
http://dx.doi.org/10.1016/j.ejr.2013.12.002Open access under CC BY-NC-ND license.Samah A. El Bakry a,*, Amina Bader El Din a, Al Hussein M. El Dakrony b,
Nouran M. Abaza c, Rania A. Abo-Shady d, Nesrine A. Mohamed d,
Ola H. Nada ea Internal Medicine and Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
b Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Cairo, Egypt
c Rheumatology and Rehabilitation Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
d Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
e Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptReceived 7 December 2013; accepted 16 December 2013
Available online 13 January 2014KEYWORDS
Anti-nucleosome antibodies;
SLE;
Lupus nephritis;
SLEDAIAbstract Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus
erythematosus (SLE). Clinical renal involvement is present in about two-thirds of lupus patients
and more patients would have morphologic evidence of renal disease without clinical manifesta-
tions.
Aim of the work: To investigate serum anti-nucleosome antibodies role as a biomarker for renal
affection in lupus patients with insigniﬁcant proteinuria.
Patients and methods: Twenty-four lupus patients with proteinuria <500 mg/d (group-A), 30
patients with established lupus nephritis (group-B) and 15 controls were included. Systemic lupus
erythematosis disease activity index (SLEDAI), anti-nucleosome, anti-dsDNA antibodies and renal
biopsy were assessed in all patients.
Results: Serum anti-nucleosome antibodies were signiﬁcantly higher in all lupus patients than
control (P< 0.001) and showed signiﬁcant positive correlation with SLEDAI score. SLE patients
80 S.A. El Bakry et al.with positive anti-dsDNA antibody had more active disease by SLEDAI and higher levels of anti-
nucleosome antibodies than those with negative anti-dsDNA antibodies. In both studied groups,
serum anti-nucleosome antibodies were signiﬁcantly higher in patients with class II LN than the
control and in class III LN than in class II LN (P< 0.001). Yet, in both groups, anti-nucleosome
was not useful in differentiating active from chronic renal affection.
Conclusion: Serum levels of anti-nucleosome antibodies are associated with active lupus disease
and correlate with the degree of renal affection. In patients with insigniﬁcant proteinuria, serum lev-
els of anti-nucleosome antibodies were elevated and were related to the degree of renal affection.
Anti-nucleosome antibodies may be used as a surrogate marker for early renal affection in lupus
patients with insigniﬁcant proteinuria.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic inﬂammatory
autoimmune disease that affects mostly all organs of the body
[1]. Lupus nephritis (LN) is one of the most serious manifesta-
tions in SLE and it occurs in about 60% of patients. Patients
with LN have increased risk of progressive deterioration of
kidney function as well as increased mortality rates [2]. The
most important feature in LN is immune complex deposition
in renal glomeruli which produces glomerular inﬂammation.
The site and the amount of these immune deposits determine
the degree and class of LN [3].
Given the heterogeneity of the disease, many mechanisms
have been postulated for formation of glomerular immune
complexes [4–6]. One of our interests is the presence of anti-
chromatin autoantibodies (anti-nucleosome, anti-histone and
anti-DNA) which are present in 75% of patients with SLE
and up to 100% of patients with drug-induced lupus [7].
Nucleosomes, released by apoptosis, bind to the mesangial ma-
trix and glomerular basement membranes and may represent a
relevant source of autoantigens. Thus, these apoptotic nucleo-
somes may serve both as an inducer and a major target for
nephritogenic autoantibodies in SLE [8].
Several studies have discussed the role of anti-nucleosome
antibodies (ANuA) in the diagnosis and assessment of disease
activity in SLE, as well as its role in evaluating severity of SLE
renal disease requiring transplantation [9–11]. In a systematic
review and meta analysis, Bizzaro and colleagues showed that
the overall sensitivity of the ANuA assay is 61% and the
speciﬁcity is 94%. This suggests that antibodies have equal
speciﬁcity but higher sensitivity and prognostic value than
anti-dsDNA antibodies in the diagnosis of SLE [10]. As well,
ANuA have been investigated as a biomarker for the evalua-
tion of active proliferative LN. It was found that those anti-
bodies have a high prevalence in patients with severe lupus
nephritis but its role in differentiating patients with active
LN from those with inactive renal disease is still questionable
[12,13].
Signiﬁcant renal affection in SLE can occur before impair-
ment of kidney function or changes in laboratory parameters.
Christopher-Stine et al., studied the renal biopsies of 21 lupus
patients with low levels of proteinuria and found signiﬁcant re-
nal involvement (Class III, IV, or V LN) in SLE patients with
<1000 mg proteinuria with or without hematuria [14].
Unfortunately, the use of conventional clinical parameters
such as creatinine clearance, proteinuria, urine sediments,
anti-dsDNA and complement levels did not help much in thedetection of ongoing disease activity in the lupus kidneys or
diagnosis of early relapse of nephritis. Although renal biopsy
is important for the diagnosis of histological class of LN, yet
it has its limitations and contraindications. Thus, new
biomarkers are needed to improve the diagnostic accuracy
and sensitivity of lupus renal disease, monitoring of treatment
response, and detection of early renal ﬂares [15].
In this study, we investigated the potential role of serum
anti-nucleosome antibodies as a marker for the detection of re-
nal involvement in SLE patients with insigniﬁcant proteinuria
and its correlation with the WHO pathological classes.
2. Patients and methods
2.1. Study design
This is a cross sectional-observational study.
2.2. Clinical evaluation
A total of 54 Egyptian lupus patients were consecutively
enrolled along with 15 healthy subjects (age and sex matches)
who served as a control group for serum anti-nucleosome anti-
body. All lupus patients were recruited from the rheumatology
clinic-internal medicine department-Ain Shams University,
rheumatology and rehabilitation clinic-Cairo University and
rheumatology and rehabilitation clinic-Ain Shams University.
All patients fulﬁlled 1997 revised criteria of the American Col-
lege of Rheumatology (ACR) for SLE [16]. Patients were
recruited between October 2011 and December 2012. All par-
ticipants gave written informed consent to participate in the
study, which was approved by our local Ethics Committee.
Twenty-four lupus patients with proteinuria less than
500 mg/24 h and normal urine analysis were set for group A.
Thirty lupus patients with clinical renal involvement were set
for group B. All patients were subjected to full medical history
and thorough clinical examination (general, systemic and mus-
culoskeletal). Assessment of SLE disease activity was done by
using the systemic lupus erythematosus disease activity index
(SLEDAI) [17].
2.3. Laboratory assessment
Venous blood (8 ml) was withdrawn from each patient where,
5 ml was placed in EDTA tube for performing complete blood
count (CBC) and erythrocyte sedimentation rate (ESR) and
Table 1 Laboratory data and pathological data of the
systemic lupus erythematosus patients with proteinuria less
than 500 mg/24 h (group-A) and clinical renal involvement
(group B).
Parameter (mean ± SD) Systemic lupus erythematosus patients
Group-A (n= 24) Group-B (n= 30)
Hb (gm/dl) 9.3 ± 1.2 10.7 ± 1.6
WBCs (·103) 5.9 ± 3.0 7.11 ± 1.6
Platelets (·103) 188.3 ± 62.6 291.6 ± 100.3
ESR (mm/1st hr) 103.3 ± 32.5 71.7 ± 26.6
ANA 858.0 ± 334.1 950.8 ± 410.0
Prot/cr (gm/ml) 0.18 ± 0.03 3.33 ± 2.61
SLEDAI 12.0 ± 4.1 6.2 ± 1.9
A Nu A (U/ml) 78.3 ± 43.6 86.2 ± 40.3
Activity index 3.4 ± 0.7 6.7 ± 04.9
Chronicity index 2.8 ± 0.8 2.9 ± 1.5
Hb, hemoglobin; WBCs, white blood cells; ESR, erythrocyte
sedimentation rate; ANA, anti nuclear antibodies; ANuA, serum
anti-nucleosome antibodies; SLEDAI score, systemic lupus
erythematosis disease activity index.
Anti-nucleosome antibodies and the diagnosis of lupus nephritis 813 ml of blood was collected in plain vacutainers for analysis of
ANA, anti-dsDNA and anti-nucleosome antibodies. Serum
samples were stored at 20 C until the time of assay. CBC
was done using Coulter counter (T660), ESR was done by
the Westergren method. ANA and anti-dsDNA were per-
formed by indirect immunoﬂuorescence assay using IMMCO
Diagnostics, USA (ANA on Hep-2 substrate and anti-dsDNA
on Crithidia luciliae substrate). ANuA were assayed using the
QUANTA Lite Chromatin ELISA Kit (INOVA Diagnostics,
Inc. USA) according to the manufacturer’s instructions where
serum values <20 U/ml were considered negative, values
between 20 and 60 were considered moderately positive and
values >60 U/ml were considered strongly positive.
2.4. Renal histopathological assessment for LN
The renal tissue was obtained from all lupus patients and eval-
uated by light microscopy by one pathologist. The biopsies
were graded according to the classiﬁcation of lupus nephritis
by the International Society of Nephrology/Renal Pathology
Society (ISN/RPS) [18] in which normal glomeruli are desig-
nated as class I lupus nephritis while mesangial hypercellular-
ity represents class II and a state of lupus nephritis showing
focal or diffuse segmental or global endo- or extracapillary
glomerulonephritis, with or without mesangial alterations is
classiﬁed as class III (focal lupus nephritis) and class IV (Dif-
fuse lupus nephritis), respectively. Membranous nephritis is
categorized as class V and class VI is characterized by ad-
vanced sclerosis. Activity and chronicity scores are used
according to Austin et al. [19].
Statistical methods: Statistical analysis was performed using
IBM SPSS statistics (V. 21.0, IBM Corp., USA, 2012). Data
were expressed as Mean ± SD for quantitative parametric
measures in addition to median percentiles for quantitative
non-parametric measures and both number and percentage
for categorized data. Wilcoxon Rank Sum test was used for
comparison between two independent groups for non-para-
metric data. Wilcoxon signed rank test was used for compari-
son between two dependent groups for non-parametric data.
Comparison between pathological LN groups for non-para-
metric data was done by using the Kruskall Wallis test.
Ranked Spearman correlation test was used to study the pos-
sible association between each of the two variables among each
group for non-parametric data. Chi-square test was used to
study the comparison between patients with and those without
LN as regards the categorized data. P value <0.05 indicated
statistical signiﬁcance while P< 0.01 and 0.001 indicated high
statistical signiﬁcance.
3. Results
3.1. Clinical and laboratory data of SLE patients
Twenty-four lupus patients with proteinuria less than 500
mg/24 h and normal urine analysis were included in group-A
(20 females and 4 males) and their mean age was 24.54 ±
3.93 years. Thirty lupus patients with established renal disease
were included in group-B (all females) and their mean age was
29.4 ± 5.8 years. Other characteristics of both groups are dis-
played in Table 1. Serum levels of ANuA were signiﬁcantly
higher in lupus patients, both groups A and B, than the controlgroup (78.3 ± 43.6 and 86.2 ± 40.3 versus 14.6 ± 8.8 U/ml,
respectively; P< 0.001).
3.2. Correlation between anti-nucleosome antibodies and lupus
disease activity
Using ranked Spearman test (Table 2), serum ANuA levels in
group-A patients showed a signiﬁcant correlation with ESR
and highly signiﬁcant correlation with the SLEDAI, while in
group-B the levels showed highly signiﬁcant correlation with
the SLEDAI and both pathological activity and chronicity
indices whereas there was a signiﬁcant negative correlation
with hemoglobin levels. In group-A, 20 patients had positive
and 4 had negative anti-dsDNA antibodies, while it was 15
and 15, respectively in group-B (data not shown). Using
Wilcoxon signed rank test (Table 3), we found that patients
with positive anti-dsDNA antibodies had more active disease
presented by higher SLEDAI and levels of ANuA than those
with negative anti-dsDNA antibodies. This was found in both
groups.
3.3. Relation of anti-nucleosome antibodies and renal
histopathological changes
In group-A, only 20 patients agreed to do renal biopsy, eight
(40%) had class II LN and 12 (60%) had class III. Patients
with class II LN had statistically higher levels of ANuA than
the controls (52.1 ± 5.5 and 14.6 ± 8.8 U/ml, respectively;
P< 0.001). Moreover, levels of ANuA were much higher in
patients who had class III LN than those with class II LN
(116.1 ± 23.5 and 52.0 ± 5.5 U/ml, respectively; P< 0.001)
(Fig. 1). In group-B, eight patients (26.7%) had class II LN,
eight (26.7%) had class III and 14 patients (46.6%) had class
IV. Patients with class II LN had statistically higher levels of
ANuA than the controls (35.6 ± 7.5 and 14.6 ± 8.8 U/ml,
respectively; P< 0.001). As well, levels of ANuA were much
higher in patients with class III and IV than those with class
II LN (100.6 ± 38.4 and 106.8 ± 25.4 vs. 35.6 ± 7.4 U/ml,
Table 2 Correlation between serum anti-nucleosome antibodies and data of disease activity in lupus patients with proteinuria less
than 500 mg/24 h (group-A) and clinical renal involvement (group B).
Parameter Systemic lupus erythematosus patients
Group-A (n= 24) Group-B (n= 30)
r p r p
Hb (gm/ml) 0.172 0.422 0.482 0.007**
ESR (mm/1sthr) 0.413 0.045* 0.207 0.272
SLEDAI score 0.545 0.006** 0.471 0.009**
Activity index 0.046 0.848 0.516 0.004**
Chronicity index 0.043 0.856 0.587 0.001**
Hb, hemoglobin; ESR, erythrocyte sedimentation rate; SLEDAI score, systemic lupus erythematosis disease activity index.
* Signiﬁcant.
** Highly signiﬁcant.
Table 3 Correlation between anti-dsDNA positivity with
SLEDAI and serum anti-nucleosome antibodies’ levels in lupus
patients with proteinuria less than 500 mg/24 h (group-A) and
clinical renal involvement (group B).
Parameter Systemic lupus erythematosus patients
Group-A Group-B
Z p Z p
SLEDAI 3.191 0.001** 4.916 0**
ANuA (U/ml) 3.101 0.002** 2.034 0.042*
SLEDAI, systemic lupus erythematosis disease activity index;
ANuA, serum anti-nucleosome antibodies.
* Signiﬁcant.
** Highly signiﬁcant.
82 S.A. El Bakry et al.respectively; P= 0.001) (Fig. 2). Yet, there was no signiﬁcant
difference in anti-nucleosome levels between patients who had
class III LN and those with class IV LN (Z= 1.059 and
P= 0.289).
4. Discussion
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease with multi-organ affection and diversity of clinical pre-
sentations as well as unpredictable course [20]. Kidney disease
is a central and serious complication with glomerulonephritis
as a major cause of morbidity and mortality in patients with
SLE [21]. The most important mechanism in developing LN
is the formation of immune complexes. Deposition of circulat-
ing immune complexes or its formation in situ will produce
glomerular inﬂammation which will depend on the site and
amount of theses immune deposits [3]. In SLE, DNA is a ma-
jor component of the serum nucleosome and its potential con-
tribution is through apoptosis, necrosis and Neutrophil
extracellular traps’ induced apoptosis (NETosis) [22]. Serum
nucleosomes released by apoptotic cells can serve as major
auto-antigens for T and B cells. Those nucleosomes recognize
heparin sulfate/collagens components of the glomerular base-
ment membrane and facilitate binding of anti-nucleosome
and other nephritogenic antibodies [23,24]. Electron micro-
scopic examination of renal biopsies from patients with lupus
nephritis showed that auto-antibodies attached the extracellu-
lar deposits of chromatin, conﬁrming the suggestion that intra-
glomerular membrane-associated nucleosomes are targeted by
nephritogenic antibodies [25].
In this study serum levels of ANuA were signiﬁcantly high-
er in lupus patients (both groups A and B) than the controls.
Several studies have discussed role of ANuA in the diagnosis
of SLE as well as its role in monitoring lupus disease activity
[26–28]. Testing for ANuA may serve as a sensitive and speciﬁc
tool in the diagnosis of SLE, especially when the anti-dsDNA
antibodies are absent [25].
We have demonstrated that the higher the serum level of
ANuA, whether there is renal involvement or not, the more ac-
tive the disease is. Moreover, we found that patients with po-
sitive anti-dsDNA antibodies had higher levels of serum
ANuA than those with negative anti-dsDNA antibodies. Sim-
ilarly, Sardeto et al., in his study of Brazilian SLE population,
found a positive relationship between serum level of ANuAand disease activity measured by SLEDAI and anti-dsDNA
presence [28].
Clinical renal involvement is present in about two-thirds of
lupus patients and it carries signiﬁcant morbidity and mortal-
ity [29]. Despite the improvement of treatment protocols, the
outcome of lupus nephritis is still not rewarding and about
25% of lupus patients will have end stage renal disease within
10 years of diagnosis [30]. The frequency of end stage renal dis-
ease in patients with proliferative nephritis is much higher than
those with other classes of nephritis [31]. Moreover, many
studies have suggested that a higher percentage of lupus
patients would have morphologic evidence of renal disease
without clinical manifestations. This condition has been re-
ferred to as silent lupus nephritis and it was only diagnosed
by renal biopsy [32–35]. Wakasugi et al. studied the renal biop-
sies of 195 lupus patients including 86 with no clinical data of
renal involvement and found that 58% of lupus patients with
no clinical renal affection had class I nephritis while 15% of
this group had classes III and IV nephritis [36]. In the current
study, 54 lupus patients were included, 24 patients with no
clinical manifestations of renal affection, group-A, and 30
patients with clinical lupus nephritis (group-B). In group-A,
40% had class II nephritis, while 60% had class III. In
group-B, 53.4% had classes II and III nephritis and 46.6%
had class IV.
The relationship between ANuA and the degree of renal
disease activity has been investigated by many [12,13,37].
Bigler et al. measured levels of ANuA in 35 patients with active
Figure 1 Comparison between lupus group-A patients (with proteinuria less than 500 mg/24 h) and control as regards the anti-
nucleosome antibodies levels.
Figure 2 Comparison between lupus group-B patients (with clinical renal involvement) and control as regards the anti-nucleosome
antibodies levels.
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controls of SLE who had inactive or no nephritis and found
that ANuA have a high prevalence in patients with severe
lupus nephritis but are of limited help in the distinction be-
tween patients with active proliferative lupus nephritis and
those without active renal disease [12]. In another recent study,
ANuA were found to be correlated with the activity index of
proliferative LN but not with the chronicity index [13]. In
our study, we have demonstrated that serum levels of ANuA
correlated with the degree of renal affection, as in all studied
lupus patients, serum level of ANuA was statistically higher
in patients with mesangioproliferative nephritis than the con-
trols. Moreover, it was statistically higher in patients with pro-
liferative nephritis than those with mesangioproliferative
nephritis. Yet, in both groups of lupus patients, anti-nucleo-
some was not useful in differentiating active from chronic renal
affection.
In conclusion, serum levels of ANuA are associated with
active lupus disease and correlate with the degree of renalaffection. Moreover, in patients with insigniﬁcant proteinuria,
serum levels of ANuA were elevated and were related to the
degree of renal affection. The data presented here suggest that
ANuA may be used as a surrogate marker for early renal affec-
tion in lupus patients with insigniﬁcant proteinuria. However,
more follow up studies on larger number of patients are
needed to conﬁrm this and to study the correlation with other
disease parameters such as the presence of antiphospholipid
syndrome and damage index as well as the response to therapy.
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